Market Research Logo

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Summary


Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach and is the fifth-most common cancer globally. There are many types of gastric cancer, but adenocarcinoma is the most common type and is diagnosed in 95% of cases. The life expectancy and survival rate for gastric cancer is heavily dependent on the stage of the disease when diagnosed. In Asia-Pacific, most of the incident cases of gastric cancer are diagnosed at the late stage and in patients over the age of 60. As the aged population continues to grow, the prevalence of gastric cancer will increase. This, coupled with increasing early diagnosis and an improved survival rate, will drive revenue growth. Due to its indolent nature, the disease remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved targeted therapeutic options. The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.

In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.

Scope

The Asia-Pacific gastric cancer market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.

  • How will angiogenesis inhibitors contribute to growth?
  • What effect will the patent expirations of branded therapies have on market value?
The pipeline contains a range of molecule types and molecular targets, including those that are well-established in gastric cancer and novel targeted therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
  • What are the most promising first-in-class targets for gastric cancer?
  • Will the current first-in-class targets have broader therapeutic potential across the Asia-Pacific markets?
  • Will the pipeline address unmet needs such as a lack of targeted treatments for HER2-negative gastric cancer patients?
Various drivers and barriers will influence the market over the forecast period.
  • What are the barriers that limit the uptake of premium-priced targeted therapeutics in the assessed countries?
  • Which factors are most likely to drive the market in these countries?
Licensing deals are the most common form of strategic alliance in gastric cancer, with total deal values ranging from under $10m to over $200m.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict gastric cancer market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals.


Asia-Pacific gastric cancer market set to experience strong growth to $2.7 billion by 2022, says GBI Research

The Asia-Pacific (APAC) gastric cancer market is set to rise from $1.3 billion in 2015 to $2.7 billion by 2022, at a strong compound annual growth rate of 11.4%, according to business intelligence provider GBI Research.

The company’s latest report states that the market will be driven by the increasing prevalence of gastric cancer, higher levels of health insurance coverage, and improving disease awareness. Indeed, strong awareness of the disease and a widespread screening program in Japan have already led to a higher number of cases being diagnosed at stage I, increasing the treatment-receiving population.

Gayathri Kanika, Analyst for GBI Research, states: “In line with improved diagnosis rates, the anticipated approval of various monoclonal antibodies (mAbs) over the forecast period will drive treatment rates across all lines of therapy and generate higher sales in the gastric cancer market.

“Currently, the gastric cancer treatment landscape largely comprises generic chemotherapies, which provide limited clinical benefit and cause serious side effects. However, the current pipeline is strong, with targeted therapies expected to be launched during the forecast period.”

A new class of drug approved for the treatment of gastric cancer, targeting vascular endothelial growth factor receptor, is Cyramza (ramucirumab), a mAb used for second- and third-line therapy for gastric cancer. GBI Research expects Cyramza to garner rapid uptake, as it is being established as the standard of care for the second-line advanced setting, with its label expected to expand to cover the HER2-negative first-line setting within the forecast period.

Perjeta (pertuzumab) is being developed in combination with Herceptin for the treatment of gastric cancer, on the assumption that the combination will yield superior results. The response rate shown in a Phase II trial – which compared the efficacy of Herceptin/Perjeta combination with that of Herceptin plus chemotherapy – was higher for the Herceptin/Perjeta combination. Perjeta, once approved, will likely replace the current standard of first-line treatment for HER2-positive gastric cancer.

Kanika concludes: “Despite their promise, the anticipated premium pricing of mAbs will make affordability a barrier for the marketing of these drugs in India and China, where there are no strong reimbursement frameworks and most expenses are paid out-of-pocket by the patient.

“Moreover, increasing cost-consciousness in the other major Asian markets, such as Japan and South Korea, will limit premium pricing opportunities for pipeline agents. Drug companies will need to consider the changing reimbursement landscape when determining the pricing strategies for their drugs in these markets.”

  • Comments provided by Gayathri Kanika, Analyst for GBI Research.
  • Information based on GBI Research’s report: Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies.
  • This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Pathophysiology
2.5.1 Helicobacter Pylori
2.5.2 Oncogenes
2.5.3 Tumor Suppressor Genes
2.5.4 Cell Adhesion Molecules and Metastasis-Related Genes
2.5.5 Cell Cycle Regulators
2.5.6 Microsatellite and Chromosomal Instability
2.5.7 Growth Factor and Cytokines
2.6 Diagnosis
2.6.1 Photofluorography or Barium Study
2.6.2 Endoscopy
2.6.3 Imaging Tests
2.6.4 Endoscopic Ultrasound
2.6.5 Laparoscopy
2.6.6 Laboratory Analysis
2.7 Classification and Disease Staging
2.7.1 Intestinal Subtype
2.7.2 Diffuse Subtype
2.8 Prognosis
2.9 Treatment Guidelines and Options
2.9.1 Surgery
2.9.2 First-Line Therapy
2.9.3 Second-Line Therapy
3 Marketed Products
3.1 Overview
3.2 HER2-Targeted Therapy
3.2.1 Herceptin (trastuzumab) – Roche/Genentech
3.3 Angiogenesis Inhibitors
3.3.1 Cyramza (ramucirumab) – Eli Lilly
3.3.2 Aitan (apatinib) – Jiangsu HengRui Medicine
3.4 Newer Chemotherapies
3.4.1 TS-1 (tegafur, gimeracil, oteracil) – Taiho
3.4.2 Abraxane (nab-paclitaxel) – Celgene/Taiho
3.5 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Opdivo (nivolumab) – Ono Pharmaceutical/Bristol-Myers Squibb
4.4.2 Keytruda (pembrolizumab) – Merck
4.4.3 Perjeta (pertuzumab) – Roche
4.4.4 Napabucasin – Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma)
4.4.5 Lynparza (olaparib) – AstraZeneca
4.4.6 Nimotuzumab – Kuhnil Pharmaceutical/Daiichi Sankyo
4.4.7 Avelumab – Merck
4.4.8 GS-5745 – Gilead Bioscience
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitive Framework
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development and Molecule Type
5.3.2 Trial Duration by Stage of Development and Molecular Target
5.4 Summary of Clinical Trial Metrics
6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
7 Market Dynamics
7.1 Drivers
7.1.1 Increasing Prevalence and Treatment Rate Across All Lines of Therapy in the Metastatic Setting
7.1.2 Promising Drug Pipeline Focused on Targeted Therapies
7.1.3 Launch of Premium-Priced Drugs for the Metastatic Setting
7.1.4 Improved Treatment Options that Extend Duration of Therapy
7.1.5 Increasing Screening Programs and Government Reforms
7.2 Barriers
7.2.1 Lack of Development of Pipeline Agents as Pre-operative and Postoperative Treatments for Resectable Gastric Cancer
7.2.2 Patent Expiration of Herceptin and Patient Share Erosion by Trastuzumab Biosimilars
7.2.3 Affordability and Reimbursement Issues in India and China
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Deals by Year
8.2.3 Deals by Stage of Development, Molecule Type and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/ Clinical Trial Authorization-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging
Table 2: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 3: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 4: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2016
Table 5: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 6: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 7: Gastric Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 8: Gastric Cancer Therapeutics Market, Asia-Pacific, Market Forecast, 2015–2022
Table 9: Gastric Cancer Therapeutics Market, India, Market Forecast, 2015–2022
Table 10: Gastric Cancer Therapeutics Market, China, Market Forecast, 2015–2022
Table 11: Gastric Cancer Therapeutics Market, Australia, Market Forecast, 2015–2022
Table 12: Gastric Cancer Therapeutics Market, South Korea, Market Forecast, 2015–2022
Table 13: Gastric Cancer Therapeutics Market, Japan, Market Forecast, 2015–202
1.2 List of Figures
Figure 1: Gastric Cancer Therapeutics, Australia, Age-Specific Incidence Rate per 100,000 Population, 2004, 2008 and 2012
Figure 2: Gastric Cancer, Stage Grouping
Figure 3: Gastric Cancer, Market Heat Map
Figure 4: Pipeline for Gastric Cancer, Global, 2016
Figure 5: Pipeline for Gastric Cancer by Molecular Target, Global, 2016
Figure 6: Pipeline for Gastric Cancer by Molecular Target by Stage of Development, Global, 2016
Figure 7: Gastric Cancer Therapeutics Market, Asia-Pacific, Opdivo, Market Forecast ($m), 2018–2022
Figure 8: Gastric Cancer Therapeutics Market, Asia-Pacific, Keytruda, Market Forecast ($m), 2019–2022
Figure 9: Gastric Cancer Therapeutics Market, Asia-Pacific, Perjeta, Market Forecast ($m), 2018–2022
Figure 10: Gastric Cancer Therapeutics Market, Asia-Pacific, Napabucasin, Market Forecast ($m), 2018–2022
Figure 11: Gastric Cancer Therapeutics Market, Asia-Pacific, Lynparza, Market Forecast ($m), 2019–2022
Figure 12: Gastric Cancer Therapeutics Market, Asia-Pacific, Nimotuzumab, Market Forecast ($m), 2019–2022
Figure 13: Gastric Cancer Therapeutics Market, Asia-Pacific, Avelumab, Market Forecast ($m), 2020–2022
Figure 14: Gastric Cancer, Pipeline Heat Map
Figure 15: Gastric Cancer, Marketed and Pipeline Product Competitiveness Framework
Figure 16: Gastric Cancer Therapeutics Market, Global, Overall Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016
Figure 17: Gastric Cancer Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016
Figure 18: Gastric Cancer Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016
Figure 19: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type and Stage of Development, 2006–2016
Figure 20: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target and Stage of Development, 2006–2016
Figure 21: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Trial by Stage of Development and Molecule Type, 2006–2016
Figure 22: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size per Trial by Stage of Development and Molecular Target, 2006–2016
Figure 23: Gastric Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, 2006–2016
Figure 24: Gastric Cancer Therapeutics Market, Global, Clinical Trial Size by Molecular Target by Stage of Development (patients), 2006–2016
Figure 25: Gastric Cancer Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 26: Gastric Cancer Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 27: Gastric Cancer Therapeutics Market, Asia-Pacific, Treatment Patterns (‘000), 2015–2022
Figure 28: Gastric Cancer Therapeutics Market, Asia-Pacific, Market Size ($bn), 2015–2022
Figure 29: Gastric Cancer Therapeutics Market, India, Treatment Patterns (‘000), 2015–2022
Figure 30: Gastric Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2015–2022
Figure 31: Gastric Cancer Therapeutics Market, India, Market Size ($m), 2015–2022
Figure 32: Gastric Cancer Therapeutics Market, China, Treatment Patterns (‘000), 2015–2022
Figure 33: Gastric Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2015–2022
Figure 34: Gastric Cancer Therapeutics Market, China, Market Size ($bn), 2015–2022
Figure 35: Gastric Cancer Therapeutics Market, Australia, Treatment Patterns, 2015–2022
Figure 36: Gastric Cancer Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015–2022
Figure 37: Gastric Cancer Therapeutics Market, Australia, Market Size ($m), 2015–2022
Figure 38: Gastric Cancer Therapeutics Market, South Korea, Treatment Patterns (‘000), 2015–2022
Figure 39: Gastric Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015–2022
Figure 40: Gastric Cancer Therapeutics Market, South Korea, Market Size ($m), 2015–2022
Figure 41: Gastric Cancer Therapeutics Market, Japan, Treatment Patterns (‘000), 2015–2022
Figure 42: Gastric Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015–2022
Figure 43: Gastric Cancer Therapeutics Market, Japan, Market Size ($bn), 2015–2022
Figure 44: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2016
Figure 45: Gastric Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year and Aggregate Deal Value ($m), 2006–2016
Figure 46: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development and Deal Value ($m) 2006–2016
Figure 47: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2016
Figure 48: Gastric Cancer Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–2016
Figure 49: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006–2016
Figure 50: Gastric Cancer Therapeutics Market, Global, Number of Co-development Deals by Year, 2006–February 2016
Figure 51: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006–2016
Figure 52: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development, 2006–2016
Figure 53: Gastric Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–201

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report